Atara生物治疗 ATRA 深 沪
等待开盘 04-02 09:30:00 美东时间
5.17
+0.440
+9.30%
华盛通- 最 高5.25
- 今 开4.86
- 成交量 7.98万股
- 最 低 4.775
- 昨 收 4.73
- 总市值 4228.08万
- 52周最高 19.145
- 市盈率 静 2.01
- 换手率 0.00%
- 52周最低 3.92
- 委 比 68.35%
- 总股本 817.81万
- 历史最高 1639.00
- 量 比 1.23
- 振 幅 10.04%
- 历史最低 3.92
- 每 手 1
- 风险率 4.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
WALTHAM, Mass., April 01, 2026 -- Ardelyx, Inc. announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer. Dr. Dinavahi brings over two decades of experience in healthcare and biotechnology, with expertise in immuno-oncology, autoimmune diseases, metabolic disease, nephrology, and transplantation. She previously served as Chief Medical Officer at Atara Biotherapeutics. Ardelyx's president and CEO, Mike Raab, highlighted her scien...
04-01 12:01
Atara Plans FDA Type A Meeting on EBVALLO
The latest update is out from Atara Biotherapeutics ( ($ATRA) ). On March 12, 2...
03-12 20:37
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Mesoblast Limited announced the appointment of Dr. Teresa Montagut as Head of Clinical Development and Medical Affairs, tasked with advancing the company's cell therapy programs for pediatric and adult inflammatory conditions. Dr. Montagut brings extensive experience in medical leadership and cancer immunotherapy development, previously leading programs at Regeneron, Novartis, and Genentech. Mesoblast is focused on developing allogeneic cellular ...
03-11 23:21
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Relmada Therapeutics (NASDAQ:RLMD) stock rose 48.3% to $6.6 during Mon...
03-09 20:05
Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Submits Request To FDA For Type A Meeting About ALLELE Trial
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
03-03 21:27
BRIEF-Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel
BRIEF-Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel March 3 (Reuters) - Atara Biotherapeutics Inc ATRA.O : ATARA BIOTHERAPEUTICS PROVIDES REGULATORY UPDATE ON TABELECLEUCEL Source text: ID:nBwcf5zT8a Further company coverage: ATRA.O (( Reuters.Briefs@thomsonreuters.com ;))
03-03 21:12
Atara jumps amid report on FDA’s U-turn on cell therapy
Shares of Atara Biotherapeutics (ATRA) climbed on Wednesday after Stat News reported that the U.S. FDA rejected the company’s cell therapy tabelecleucel last month despite its internal reviewers recom...
02-26 02:56
Atara Biotherapeutics Extends $9 Million HCRx Milestone Payment Due Date to 2028
Atara Biotherapeutics Extends $9 Million HCRx Milestone Payment Due Date to 2028 Atara Biotherapeutics, Inc. said it entered into an amendment to its December 20, 2022 Purchase and Sale Agreement with a fund managed by HealthCare Royalty (HCRx). Under the amendment, HCRx agreed to extend the due dat
02-23 21:01
Atara's Outlook As Ebvallo Hits Second FDA CRL
Manufacturing Fixed, But Trial Interpretability Now Blocks US Approval Drug &am...
01-15 02:28
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
